The board of directors of Daxor (NYSE MKT:DXR), a medical company, on Friday authorised an annual dividend payment of USD0.03 per share for 2016.

This dividend is due on 29 December 2016 to shareholders of record as of 22 December 2016.

Additionally, the company has announced the receipt of a notice of Decision to Grant a patent for the Total Body Albumin Analyzer from The Patent Office of Japan. This provides important international protection for this invention, which was already granted under US Patent number 9,002,657 in 2015. This technology allows the calculation of Total Body Albumin to be made by the Daxor BVA-100 and extends the capabilities of this device beyond the several volume measures it provides.

In conjunction, the company has permanently confirmed the position of its acting president and chief executive officer Michael Feldschuh; Dr Joseph Feldschuh has assumed the position of chief medical officer while on temporary leave.